Welcome to LookChem.com Sign In|Join Free
  • or
NVP-LCQ195 is a potent and selective inhibitor of the novel anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) tyrosine kinases. It is a promising candidate for the treatment of ALKand ROS1-driven cancers due to its effectiveness in inhibiting the growth of tumor cells with activating mutations in the ALK and ROS1 genes. NVP-LCQ195 has a favorable safety profile and good oral bioavailability, making it a potential novel therapeutic option for patients with ALKand ROS1-positive cancers.
Used in Pharmaceutical Industry:
NVP-LCQ195 is used as an anticancer agent for the treatment of ALKand ROS1-driven cancers such as non-small cell lung cancer and anaplastic large cell lymphoma. Its effectiveness in inhibiting the growth of tumor cells with activating mutations in the ALK and ROS1 genes makes it a promising therapeutic option for these patient populations.
Used in Clinical Trials:
NVP-LCQ195 is used as a subject of ongoing clinical trials to evaluate its efficacy and safety in treating patients with ALKand ROS1-positive cancers. These trials aim to further assess the potential of NVP-LCQ195 as a novel therapeutic option for these patient populations.

902156-99-4

Post Buying Request

902156-99-4 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

902156-99-4 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 902156-99-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,0,2,1,5 and 6 respectively; the second part has 2 digits, 9 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 902156-99:
(8*9)+(7*0)+(6*2)+(5*1)+(4*5)+(3*6)+(2*9)+(1*9)=154
154 % 10 = 4
So 902156-99-4 is a valid CAS Registry Number.

902156-99-4SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 13, 2017

Revision Date: Aug 13, 2017

1.Identification

1.1 GHS Product identifier

Product name 4-[(2,6-dichlorobenzoyl)amino]-N-(1-methylsulfonylpiperidin-4-yl)-1H-pyrazole-5-carboxamide

1.2 Other means of identification

Product number -
Other names CS-0840

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:902156-99-4 SDS

902156-99-4Downstream Products

902156-99-4Relevant academic research and scientific papers

COMBINATIONS OF PYRAZOLE DERIVATIVES FOR THE INHIBITION OF CDKS AND GSK'S

-

, (2010/02/17)

A combination comprising (a) a compound of formula (0): or salts or tautomers or N-oxides or solvates thereof; wherein X is R1-A-NR4— or a 5- or 6-membered carbocyclic or heterocyclic ring; A is a bond, SO2, C═O, NR9

MEDICAL USE OF CYCLIN DEPENDENT KINASES INHIBITORS

-

Page/Page column 109-110, (2010/11/29)

The invention provides the use of a compound for the manufacture of a medicament for the treatment of pain, wherein the compound is a compound of the formula (0) : or a salt or tautomers or N-oxides or solvate thereof; wherein X is a group R1-A

PHARMACEUTICAL COMBINATIONS

-

Page/Page column 360-361, (2008/06/13)

The invention provides combinations of an ancillary compound of the formula (0): and a compound of the formula (I'): Also provided are crystalline forms of the constituent compounds, methods for making them and their uses in treating cancers.

4- (2,6-DICHLORO-BENZOYLAMINO) -1H-PYRAZOLE-3-CARBOXYLIC ACID (1-METHANESULPHONYL-PIPERIDIN-4-YL) -AMIDE FOR THE TREATMENT OF CANCER

-

, (2010/11/29)

The invention provides the compound of formula (I) 4-(2,6-dichloro-benzoylamino)-1H-pyrazole- 3-carboxylic acid (l-methanesulphonyl-piperidin-4-yl)-amide in a substantially crystalline form, therapeutic uses thereof and pharmaceutical compositions contain

PHARMACEUTICAL COMBINATIONS OF DIAZOLE DERIVATIVES FOR CANCER TREATMENT

-

Page/Page column 203-204, (2008/06/13)

The invention provides a combination comprising (or consisting essentially of) an ancillary compound and a compound of the formula (I): or salts, tautomers, solvates and N-oxides thereof; wherein: R1 is 2,6-dichlorophenyl; R2a and R

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 902156-99-4